0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > CD20 > CD0-H52H1

Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc) (HEK293)

  • Synonym
    MS4A1,CD20,MS4A-1
  • Source
    Human CD20 Full Length, His Tag (CD0-H52H1) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
    Predicted N-terminus: Met 1
  • Molecular Characterization
    Online(Met 1 - Pro 297) P11836-1

    Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins (mp,full length CD20) and membrane-associated proteins. The Nanodisc bilayer is bounded by a membrane scaffold protein (MSP1D1) coat that confers enhanced stability and a narrow particle size distribution.
    The CD20 nanodisc assembles from a mixture of full length CD20 protein in detergent, phospholipid micelles and membrane scaffold protein(MSP1D1) upon removal of the detergent.
    The CD20 carries a polyhistidine tag at the C-terminus with calculated MW of 35.2 kDa and migrates as 40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. The membrane scaffold protein(MSP1D1)has calculated MW of 24.7 kDa, and it migrates as 25 kDa under reducing (R) condition (SDS-PAGE) .

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >85% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5 . Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) SDS-PAGE gel

Human CD20 Full Length, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 85%.

Bioactivity-ELISA
Human CD20 Full Length, His TagHuman CD20 Full Length, His Tag (Cat. No. CD0-H52H1) ELISA bioactivity

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) with a linear range of 1-63 ng/mL (QC tested).

Bioactivity-FACS
FACS assay shows that recombinant Biotinylated FACS

2e5 of CD20-CAR-293 cells transfected with anti-CD20-scFv were stained with 100 μL of 3 μg/mL of Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) and negative control antibody respectively, washed and then followed by PE anti-His antibody and analyzed with FACS (QC tested).

  • Background
    B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
  • References
    • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

    Comments (0)

    Order Details

    Price(USD) : $1400.00

    Price(USD) : $5200.00

    Price(USD) : $11400.00

    Promotion & Exhibitions

    Drug Development Status

    • Number of Launched Drugs:20 Details
    • Number of Drugs in Clinical Trials:80 Details
    • Latest Research Phase:Approved

    Datasheet & Documentation

    Request for DMF
    DMF (Drug Master File)

    Contact Us

    +1  800-810-0816 (US)
    +86 400-682-2521 (AP)

    Questions & Comments

    This web search service is supported by Google Inc.

    totop